Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen's Plan to Divest Array Business Topped Most-Read GenomeWeb Daily News Stories Last Week

NEW YORK (GenomeWeb News) - What are GenomeWeb News subscribers reading? Below are the five most-read articles for the five-day period ended Friday, Sept. 21.
1. Nanogen Mulls Sale or Closure of Microarray Business in Bid to Focus on Clinical Dx (from Sept. 18)
2. Alnylam and Merck Scuttle $120M-Plus RNAi Drug-Development Partnership (from Sept. 19)
3. NIH Sets Aside $574M to Expand Translational Research Consortium (from Sept. 19)
4. Clinton, Schumer Say VA's 'Stalling' on SUNY Genebank is Getting 'Ridiculous' (from Sept. 20)
5. Agilent to License ABI's RT-PCR Thermal Cycler IP as Part of Settlement (from Sept. 19)
The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more